Hongbo Pharmaceutical: Currently, the direct revenue of the company's DiOrion platform drug research and development services accounts for a relatively small proportion of the company's overall operating income, and does not have a significant impact on the overall business situation of the company.
Hongbo Pharmaceutical announced that at the current stage, the direct revenue of the company's DiOrion platform drug development services accounts for a small proportion of the company's total operating income, and does not have a significant impact on the overall business situation of the company.
Latest
10 m ago
